2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, dubbleblind clinical trial to investigate the use of methylfenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. Secondary we will try to…